<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-7459</journal-id>
<journal-title><![CDATA[Horizonte sanitario]]></journal-title>
<abbrev-journal-title><![CDATA[Horiz. sanitario]]></abbrev-journal-title>
<issn>2007-7459</issn>
<publisher>
<publisher-name><![CDATA[Universidad Juárez Autónoma de Tabasco, División Académica de Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-74592025000100053</article-id>
<article-id pub-id-type="doi">10.19136/hs.a24n1.5917</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Perfil clínico del paciente con covid-19 grave en un hospital del noreste de México]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinical profile of the patient with severe covid-19 in a northeastern hospital in México]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Hernández]]></surname>
<given-names><![CDATA[Ramón Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Pérez]]></surname>
<given-names><![CDATA[Ricardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Maldonado-Mancillas]]></surname>
<given-names><![CDATA[Jesús Adrián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-Cruz]]></surname>
<given-names><![CDATA[Itxel Del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General Matamoros &#8220;Dr. Alfredo Pumarejo&#8221; ]]></institution>
<addr-line><![CDATA[Ciudad Victoria Tamaulipas]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General Matamoros &#8220;Dr. Alfredo Pumarejo&#8221; ]]></institution>
<addr-line><![CDATA[Matamoros Tamaulipas]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General Matamoros &#8220;Dr. Alfredo Pumarejo&#8221; ]]></institution>
<addr-line><![CDATA[Matamoros Tamaulipas]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad del Valle de México  ]]></institution>
<addr-line><![CDATA[Ciudad Victoria Tamaulipas]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2025</year>
</pub-date>
<volume>24</volume>
<numero>1</numero>
<fpage>53</fpage>
<lpage>66</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-74592025000100053&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-74592025000100053&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-74592025000100053&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Determinar el tipo de perfil clínico y la asociación de gravedad de pacientes que desarrollaron COVID 19 grave.  Materiales y Métodos: En el hospital general de la ciudad de Heroica Matamoros del Estado de Tamaulipas de los Estados Unidos mexicanos; se realizará una recolección de expedientes clínicos para ver que pacientes tuvieron previamente medicación e influyó en la mortalidad en paciente con COVID 19. Mediante un estudio retrospectivo, observacional y de cohorte, bajo la técnica de análisis estadístico; utilizando para tratamiento de la información el programa SPSS 32. Tomando en cuenta los criterios de inclusión, exclusión y eliminación definitiva.  Resultados: En el hospital general de Matamoros; de 478 que padecieron COVID 19 grave. 161 pacientes se egresaron por mejoría clínica contra 317 que consumían algún medicamento por crónico degenerativo. De 96 pacientes sin consumo de medicamentos, se observó que 34 (6.9%) egresaron por mejoría contra 63 (13.17%) que fallecieron a pesar de no consumir medicamentos. La combinación de diabetes mellitus e hipertensión resultaron 124 (25.94%) pacientes y 36 (7.53%) mejoraron, contra 88 (18.41%) defunciones.  Conclusión:  En base al presente trabajo encontramos que la polifarmacia (3 o más medicamentos), aunada a las comorbilidades; puede afectar a la administración concomitante del tratamiento base de la enfermedad por COVID 19 y tener un desfavorable desenlace. En este trabajo también registró un porcentaje similar de defunciones de pacientes que cursaban con dos o más enfermedades, contra los pacientes sanos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstratc  Objective:  To determine the type of clinical profile and the association of severity of patients who developed severe COVID-19.  Materials and methods:  In the general hospital of the city of Heroica, Matamoros, in the State of Tamaulipas of the United Mexican States; A collection of clinical records will be carried out to see which patients previously had medication and influenced mortality in patients with COVID 19. Through a retrospective, observational and cross-sectional study using the statistical analysis technique; using the SPSS 32 program for information processing. Taking into account the criteria for inclusion, exclusion and definitive elimination.  Results:  At the Matamoros General Hospital; of 478 who suffered from severe COVID 19. A total of 161 patients were discharged due to clinical improvement compared to 317 who were taking some medication due to chronic degenerative. Of the 96 patients who did not consume medications, it was observed that 34 (6.9%) were discharged due to improvement against 63 (13.17%) who died despite not consuming medications. The combination of diabetes mellitus and hypertension resulted in 124 (25.94%) patients and 36 (7.53%) improved, against 88 (18.41%) deaths.  Conclusions:  Based on the present work, we found that polypharmacy (3 or more medications), together with comorbidities; may affect the concomitant administration of the baseline treatment of COVID-19 disease and have an unfavorable outcome. In this study, he also recorded a similar percentage of deaths of patients with two or more diseases, compared to healthy patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Perfil]]></kwd>
<kwd lng="es"><![CDATA[Polifarmacia]]></kwd>
<kwd lng="es"><![CDATA[Comorbilidad]]></kwd>
<kwd lng="es"><![CDATA[Edad]]></kwd>
<kwd lng="es"><![CDATA[COVID 19]]></kwd>
<kwd lng="en"><![CDATA[Profile]]></kwd>
<kwd lng="en"><![CDATA[Polypharmacy]]></kwd>
<kwd lng="en"><![CDATA[Comorbidity]]></kwd>
<kwd lng="en"><![CDATA[Age]]></kwd>
<kwd lng="en"><![CDATA[COVID 19]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chipia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Envejecimiento y edadismo: un problema de salud pública]]></article-title>
<source><![CDATA[GICOS]]></source>
<year>2022</year>
<volume>7</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>22-3</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>INEGI</collab>
<source><![CDATA[Perfil sociodemográfico de adultos mayores]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[VELÁZQUEZ GALLARDO]]></surname>
<given-names><![CDATA[A. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La desatención médica de enfermedades crónicas provocada por la presencia de la COVID-19 en México]]></article-title>
<source><![CDATA[Trayectorias Humanas Trascontinentales]]></source>
<year>2022</year>
<numero>13</numero>
<issue>13</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sattar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[McInnes]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2020</year>
<volume>142</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atkins]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Masoli]]></surname>
<given-names><![CDATA[JAH]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pilling]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Kuo]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Kuchel]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort]]></article-title>
<source><![CDATA[J Gerontol A Biol Sci Med Sci]]></source>
<year>2020</year>
<volume>75</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2224-30</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robb]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Goepp]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19]]></article-title>
<source><![CDATA[Br J Pharmacol]]></source>
<year>2020</year>
<volume>177</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>4899-920</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Manejo clínico de la COVID-19]]></source>
<year>2021</year>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dhingra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Charan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Islam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Double Burden of the COVID-19 Pandemic and Polypharmacy on Geriatric Population - Public Health Implications]]></article-title>
<source><![CDATA[Ther Clin Risk Manag]]></source>
<year>2020</year>
<volume>16</volume>
<page-range>1007-22</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández Ugalde]]></surname>
<given-names><![CDATA[Felipe]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Escobar]]></surname>
<given-names><![CDATA[María del Carmen]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Leyva Grecia]]></given-names>
</name>
<name>
<surname><![CDATA[Junco Sánchez]]></surname>
<given-names><![CDATA[Víctor Luís]]></given-names>
</name>
<name>
<surname><![CDATA[Valdés Gasmury]]></surname>
<given-names><![CDATA[Ivette]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo Ruiz]]></surname>
<given-names><![CDATA[Maricela]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polifarmacia en el anciano. Retos y soluciones]]></article-title>
<source><![CDATA[Rev. Med. Electrón]]></source>
<year>2018</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2053-70</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iloanusi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mgbere]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Essien]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polypharmacy among COVID-19 patients: A systematic review]]></article-title>
<source><![CDATA[J Am Pharm Assoc]]></source>
<year>2021</year>
<volume>61</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>e14-25</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sirois]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Boiteau]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Gilca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Simard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exploring the associations between polypharmacy and COVID-19-related hospitalisations and deaths: a population-based cohort study among older adults in Quebec, Canada]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2022</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nwanaji-Enwerem]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Boyer]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Olufadeji]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polypharmacy Exposure, Aging Populations, and COVID-19: Considerations for Healthcare Providers and Public Health Practitioners in Africa]]></article-title>
<source><![CDATA[Int J Environ Res Public Health]]></source>
<year>2021</year>
<volume>18</volume>
<numero>19</numero>
<issue>19</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McQueenie]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[HME]]></given-names>
</name>
<name>
<surname><![CDATA[Jani]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Katikireddi]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Sattar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pell]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2020</year>
<volume>15</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poblador-Plou]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Carmona-Pírez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ioakeim-Skoufa]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Poncel-Falcó]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bliek-Bueno]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cano-Del Pozo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain]]></article-title>
<source><![CDATA[Int J Environ Res Public Health]]></source>
<year>2020</year>
<volume>17</volume>
<numero>14</numero>
<issue>14</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2020</year>
<volume>323</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1061-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iloanusi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mgbere]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Essien]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polypharmacy among COVID-19 patients: A systematic review]]></article-title>
<source><![CDATA[J Am Pharm Assoc (2003)]]></source>
<year>2021</year>
<volume>61</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>e14-25</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fanning]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Obonyo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yamashita]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Appadurai]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 Critical Care Consortium Investigators. Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study]]></article-title>
<source><![CDATA[BMC Cardiovasc Disord]]></source>
<year>2022</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>123</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alcocer]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Cossio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Verdejo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[De los Ríos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Galván]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 y el sistema renina, angiotensina, aldosterona. Una relación compleja]]></article-title>
<source><![CDATA[Arch. Cardiol. Méx]]></source>
<year>2020</year>
<volume>90</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>19-25</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alcocer-Díaz-Barreiro]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<name>
<surname><![CDATA[Cossio-Aranda]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<name>
<surname><![CDATA[Verdejo-Paris]]></surname>
<given-names><![CDATA[Juan]]></given-names>
</name>
<name>
<surname><![CDATA[Ríos]]></surname>
<given-names><![CDATA[Manuel Odin-de-los]]></given-names>
</name>
<name>
<surname><![CDATA[Galván-Oseguera]]></surname>
<given-names><![CDATA[Héctor]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez-López]]></surname>
<given-names><![CDATA[Humberto]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 y el sistema renina, angiotensina, aldosterona. Una relación compleja]]></article-title>
<source><![CDATA[Arch. Cardiol. Méx]]></source>
<year>2020</year>
<volume>90</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-25</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lei]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Qin]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19]]></article-title>
<source><![CDATA[Circulation Research]]></source>
<year>2020</year>
<volume>126</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1671-81</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Pranata]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression]]></article-title>
<source><![CDATA[Diabetes Metab Syndr]]></source>
<year>2020</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>395-403</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parveen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sehar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bajpai]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of diabetes and hypertension with disease severity in covid-19 patients: A systematic literature review and exploratory meta-analysis]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2020</year>
<numero>166</numero>
<issue>166</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Boulton]]></surname>
<given-names><![CDATA[AJM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes and COVID 19 in South-East Asia]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2020</year>
<volume>166</volume>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pablos]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Galindo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Carmona]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2020</year>
<volume>79</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1544-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Little]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-steroidal anti-inflammatory drugs and covid-19]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2020</year>
<volume>368</volume>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guan]]></surname>
<given-names><![CDATA[W-j]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[W-h]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2020</year>
<volume>55</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arora]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Anikhindi]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Bansal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis]]></article-title>
<source><![CDATA[Diabetes Metab Syndr]]></source>
<year>2020</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>535-45</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loannidis John]]></surname>
<given-names><![CDATA[P.A]]></given-names>
</name>
<name>
<surname><![CDATA[Axfor]]></surname>
<given-names><![CDATA[Cathrine]]></given-names>
</name>
<name>
<surname><![CDATA[Contopoulos-Ioannidis]]></surname>
<given-names><![CDATA[Despina G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters]]></article-title>
<source><![CDATA[Environmental Research]]></source>
<year>2020</year>
<volume>188</volume>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
